Biocurious: Lung imager Cyclopharm is breathing easy in the US market
After a 16-year wait for the US Food and Drug Administration (FDA) to approve its lung imaging tool, Cyclopharm (ASX:CYC) is ...
Zacks.com on MSN8h
Merck Q4 Earnings Coming Up: Buy, Hold or Sell MRK Stock Now?
Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus ...
Medscape11h
Nicotinamide Riboside Relieves Airway Inflammation in COPD
A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...
The American Journal of Managed Care7h
Emerging Therapies Shine Hope on Small Cell Lung Cancer Treatment
Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...
Healio9h
Six-month asthma control score on mepolizumab predicts remission in eosinophilic asthma
Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...
tisch.nyu.edu14h
Education | NYU Grossman School of Medicine | NYU Langone Health
At NYU Grossman School of Medicine, our commitment to innovation has led us to bold new ways of bridging the gap between basic science research, medical education, and quality of patient care. With ...